Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

989
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
989
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

909
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
909
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Questionnaire survey on severe hypoglycemia in pediatric patients with diabetes-English version.

Diabetology international·2024
Same author

Graves' disease coexisted with resistance to thyroid hormone: a case report.

Journal of medical case reports·2021
Same author

Heterogeneous nature of diabetes in a family with a gain-of-function mutation in the ATP-binding cassette subfamily C member 8 (ABCC8) gene.

Endocrine journal·2018
Same author

Overt diabetes mellitus caused by the topical administration of dexamethasone ointment on the oral mucosa.

Internal medicine (Tokyo, Japan)·2014
Same author

Mediastinal thyroid goiter with no accumulation on scintigraphy.

Internal medicine (Tokyo, Japan)·2013
Same author

Autoimmune polyglandular syndrome type 3 with anorexia.

Case reports in endocrinology·2013
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.9K

[Sulfonylurea].

Rika Usuda

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |March 28, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Sulfonylureas (SU) drugs effectively lower blood sugar by stimulating insulin secretion from pancreatic beta cells. Recent research explores new therapeutic potentials and proper usage for SU drugs in diabetes management.

    More Related Videos

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
    08:03

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

    Published on: June 25, 2017

    20.9K
    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
    05:58

    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

    Published on: June 25, 2019

    8.1K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.9K
    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
    08:03

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

    Published on: June 25, 2017

    20.9K
    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
    05:58

    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

    Published on: June 25, 2019

    8.1K

    Area of Science:

    • Endocrinology
    • Pharmacology

    Context:

    • Sulfonylureas (SU) are potent oral hypoglycemic agents, widely used since 1957, especially in Japan for type 2 diabetes linked to reduced insulin secretion.
    • Despite their efficacy and cost-effectiveness, issues like prolonged hypoglycemia, obesity, and secondary failure necessitate a re-evaluation of their use.

    Purpose:

    • To re-evaluate the positioning and proper usage of SU drugs in light of recent scientific advancements.
    • To explore the evolving understanding of SU drug mechanisms and their therapeutic potential.

    Summary:

    • SU drugs enhance insulin secretion by acting on pancreatic beta cells via K(ATP) channels.
    • Recent discoveries, including the clarification of K(ATP) channel structure and the identification of Epac2 as an SU drug binding protein, offer new insights into their action.
    • Understanding the interaction with Epac2 sheds light on the relationship between SU drugs and incretin-mediated insulin secretion enhancement.

    Impact:

    • This re-evaluation aims to optimize the clinical application of SU drugs, potentially improving patient outcomes and addressing current limitations.
    • The findings may lead to revised guidelines for SU drug usage, enhancing their role in managing type 2 diabetes.
    • New therapeutic strategies involving SU drugs could emerge from a deeper understanding of their molecular targets and interactions.